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Abstract 
One of the biggest challenges in regenerative medicine is promoting sufficient vascularisation of 
tissue-engineered constructs. One approach to overcome this challenge is to target the cellular 
Hypoxia Inducible Factor (HIF-1α) pathway, which responds to low oxygen concentration 
(hypoxia) and results in the activation of numerous pro-angiogenic genes including vascular 
endothelial growth factor (VEGF). Cobalt ions are known to mimic hypoxia by artificially 
stabilising the HIF-1α transcription factor. Here, resorbable bioactive glasses particles (38 µm 
and 100 µm) with cobalt ions incorporated into the glass network were used to create bioactive 
glass -collagen–glycosaminoglycan scaffolds optimised for bone tissue engineering. Inclusion of 
the bioactive glass improved the compressive modulus of the resulting composite scaffolds while 
maintaining high degrees of porosity (>97%). Moreover, in vitro analysis demonstrated that the 
incorporation of cobalt bioactive glass with a mean particle size of 100µm significantly enhanced 
the production and expression of VEGF in endothelial cells, and cobalt bioactive glass/collagen–
glycosaminoglycan scaffold conditioned media also promoted enhanced tubule formation. 
Furthermore, our results prove the ability of these scaffolds to support osteoblast cell 
proliferation and osteogenesis in all bioactive glass/collagen–glycosaminoglycan scaffolds 
irrespective of the particle size. In summary, we have developed a hypoxia-mimicking tissue-
engineered scaffold with pro-angiogenic and pro-osteogenic capabilities that may encourage bone 
tissue regeneration and overcome the problem of inadequate vascularisation of grafts commonly 
seen in the field of tissue engineering. 
Keywords: Collagen; Scaffold; Bioactive Glass; Cobalt; Angiogenesis; Regenerative 
Medicine 
 
 
 
 
 
  3 
1. Introduction 
For bone repair, the surgeons preferred choice of a bone substitute remains the bone graft, 
specifically the autograft, creating an elevated demand for these materials worldwide. The main 
disadvantage associated with this approach is the requirement of an extra surgery to harvest the 
autologous bone, and the pain associated with the harvest site is often said to be more painful 
than the recipient site [1]. Hence, the field of regenerative medicine aims to address this issue by 
developing new substitutes that can activate the body’s own natural repair process omitting the 
need for donor tissue [2]. Scaffolds provide sites for cell attachment, mechanical stability within 
the defect site, and a porous and interconnected pore network for interaction with the host (for 
cell migration, and nutrient and waste removal) [3]. In our laboratory, we have developed a series 
of scaffolds from type I collagen and the abundant polysaccharide, glycosaminoglycan, to 
produce highly porous collagen–glycosaminoglycan (CG) scaffolds by using a controlled freeze-
drying process [4-6]. These scaffolds have an optimised composition to facilitate osteogenesis [7] 
and have been shown to enhance bone repair in vivo in minimally loaded calvarial defects [8-10].  
The traditional role of the scaffold as simply a template for tissue formation has evolved 
and the new generation of scaffolds are increasingly being used as delivery vehicles for 
therapeutic molecules such as drugs, proteins and genes that initiate biological events leading to 
the regeneration of tissue [5]. Ions can also be classified as therapeutics; for instance, it has been 
shown that silicon (Si) and calcium (Ca) ions initiate osteogenesis when released in biologically 
relevant ranges (15–30 ppm for Si and 60–90 ppm for Ca) [11, 12].  One method of delivery is 
the release of Si and Ca ions from bioactive glasses, which are defined as inorganic surface-
active bioceramics. When exposed to biological fluids, bioactive glasses form a hydroxyl 
carbonate apatite layer; this layer then forms a bond between the bioactive glass and bone, 
imparting pro-regenerative ability to the bioactive glass allowing for bone ingrowth [11]. An 
approach to further enhance the therapeutic potential of the bioactive glass is to introduce ions 
such as strontium [13], magnesium or zinc [14], which are known to have anabolic responses in 
bone metabolism. Controlled rates of dissolution of the bioactive glass provide the 
physiologically relevant concentrations of the biologically active ions to the cells when exposed 
to body fluids [11]. 45S5 Bioglass particles, NovaBone and PerioGlas are examples of 
commercially available bioactive glass products that are used in the treatment of a wide range of 
dental and orthopaedic diseases [15].  
One of the biggest challenges faced in the field of regenerative medicine is promoting the 
growth of vasculature within engineered tissues to enable sufficient engraftment and integration 
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within the host [16]. Lack of vascularisation can lead to graft failure due to avascular necrosis. 
Methods of initiating angiogenesis include using expensive recombinant pro-angiogenic vascular 
endothelial growth factor (VEGF) proteins and genes encoding for VEGF. However, these 
approaches have had limited success due to the uncontrolled manner in which proteins are 
released, high doses of protein required, short protein half-life, low transfection efficiencies 
associated with gene-based approaches and potential safety concerns within a clinical setting [17, 
18]. Furthermore, single growth factor release has previously been shown to lead to the formation 
of immature vasculature [19]. An alternative strategy is to target the cellular Hypoxia Inducible 
Factor (HIF-1α) pathway, which responds to low oxygen concentration (hypoxia) and results in 
the activation of a cascade of pro-vasculogenic genes critical for angiogenesis, including VEGF 
mimicking the normal regenerative response [20]. Cobalt ions (Co
2+
) have the potential to mimic 
hypoxia, they artificially stabilise the transcription factor HIF-1α [20, 21], which then 
translocates into the nucleus to stimulate the upregulation of pro-vasculogenic genes such as 
VEGF [22]; this approach has been adopted as a potential neovascularisation strategy in a 
number of studies [23, 24]. Recently, cobalt-releasing bioactive glasses have been developed 
[25], and their ability to activate the HIF pathway under normoxic conditions was demonstrated 
[26]. 
The focus of this study was to incorporate cobalt bioactive glass [25] into CG scaffolds 
that have been developed and optimised for bone tissue regeneration [7, 27-29] with a view to 
improving the mechanical and structural properties of the CG scaffold and, most importantly, 
enhancing the initial angiogenic step vital for bone regeneration [30, 31]. Specifically, the aims 
were to assess the effect of the bioactive glass on the pore structure, porosity, compressive 
moduli and biological activity of the resultant composites by examining their ability to induce an 
angiogenic and osteogenic response from cells. 
 
2. Materials and Methods 
2.1 Synthesis of bioactive glass 
Bioactive glasses were synthesised in the Stevens’s laboratory in Imperial College 
London. A series of bioactive glasses containing either no cobalt or 4 mole% cobalt were 
prepared by the melt-quench route as previously described [25]. The resulting powder was sieved 
to obtain particle sizes with a mean diameter of 38 µm and 100 µm.  
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2.2 Scaffold fabrication 
A CG slurry was produced by mixing type I collagen (1.8 g) isolated from bovine tendon 
(Integra, New Jersey, USA) in 300 mL aqueous 0.5 M glacial acetic acid solution, followed by 
the dropwise addition of 0.32 g of the glycosaminoglycan chondroitin-6-sulphate sodium salt 
(Sigma-Aldrich, Ireland) dissolved in 60 mL of 0.5 M aqueous acetic acid solution [4]. The slurry 
was then degassed for a few hours. For the composites, three different types of bioactive glass 
were investigated: (1) cobalt-free with an average particle diameter of 38 m; (2) cobalt bioactive 
glass with an average particle diameter of 38 m; and (3) cobalt bioactive glass with an average 
particle diameter of 100 m. The cobalt bioactive glasses had a concentration of 4 mole% cobalt. 
The bioactive glass was suspended in distilled water at a concentration of 0.14 g/mL. Various 
volumes (0.5, 0.2 and 0.1 mL) of the bioactive glass suspension were added dropwise to 20 mL 
of the CG slurry. The slurries were homogenised at a low speed to ensure a homogeneous 
distribution of the bioactive glass, however, even at this low speed, excess air could be 
incorporated during the addition. At this stage, either the slurry was degassed a second time to 
remove excess air or the slurry was immediately frozen in a controlled manner.  
For the latter process, 2 mL of the slurry was pipetted immediately into each well of a 24-
well plate and lyophilised (Advantage EL, VirTis Co., Gardiner, NY) for 24 h using a final 
freezing temperature of –40°C. Initial freezing rates of either 1oC/min or 4oC/min were 
investigated. A range of scaffolds were fabricated by this method with final concentrations of 0, 
1.4, 2.8 and 7 mg of bioactive glass per scaffold. 
All scaffold variants were sterilised after fabrication using a dehydrothermal treatment for 
24 h at 105 °C and then further chemically crosslinked using 14 mM N-(3-
dimethylaminopropyl)-N’-ethylcarbodiimide hydrochloride) and 5.5 mM N-hydroxysuccinimide 
(Sigma-Aldrich, Ireland) in distilled water for 2 h followed by 2 x 30 min rinses in phosphate 
buffered saline (PBS) [28].  
 
2.3 Physical characterisation of bioactive glass/CG scaffolds   
2.3.1 Release of cobalt from scaffolds 
Ion Chromatography Plasma Mass Spectrometry (ICP-MS) was employed. Scaffolds 
were incubated in 5 mL TRIS buffer that was completely replaced at 24 h and then again at 7 
days. TRIS buffer collected at the 24 h and 7 day time points were frozen at –80oC until analysis. 
ICP-MS was performed on a Varian 8200 machine. All samples were run in triplicate. 
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2.3.2 Effect of bioactive glass incorporation on scaffold mechanical properties  
Compressive modulus of the scaffolds was determined using a Z050 mechanical testing 
machine (Z050, Zwick/Reoll) fitted with a 5-N load cell. Unconfined, wet compression testing 
was performed on 9-mm-diameter scaffolds with a thickness of 6–7 mm that were immersed in 
PBS and tested at a rate of 10% strain per min. The modulus was calculated from the slope of the 
stress–strain curve over the range 2–5% strain (n = 4).   
 
2.3.3 Effect of bioactive glass incorporation on scaffold porosity 
Scaffolds were embedded in JB4 glycomethacrylate resin according to manufacturer’s 
instructions (Polysciences, Germany). The embedded scaffolds were sectioned at 10 m 
thicknesses (Leica RM 2255, Leica, Germany microtome). The sections were mounted on slides 
and then stained with an aqueous 1 wt% Toludine Blue solution for 5 min. The slides were rinsed 
in distilled water and left to dry, then were mounted with coverslips using DPX mountant. The 
sections were imaged using a Nikon microscope (Optimphot2, Nikon, Japan). The pore diameters 
were determined from the images using MatLab pore topology analyser software as previously 
described [4].  
The porosity of the scaffolds with and without bioactive glass was calculated using the 
following equation: 
% porosity = 100 x [1 – (ρactual/ρtheoretical)] 
The actual density (ρactual) of the scaffolds was calculated by dividing the actual mass of the 
scaffolds by the volume of the scaffolds which was then divided by the theoretical density 
(ρtheoretical) of the materials.  
 
2.4 Biological response of bioactive glass/CG scaffolds  
2.4.1 Cell culture and seeding 
To assess the angiogenic and osteogenic response of the scaffolds, two commonly used 
cell lines were employed: (1) Human Umbilical Vein Endothelial Cells (HUVECs) were cultured 
to confluence in complete endothelial media (EGM-2, Lonza, UK) in T175 flasks (Sarstedt, 
Dublin, Ireland) under standard conditions (37
o
C, 5% CO2); (2) MC3T3-E1 cells, from a pre-
osteoblastic cell line, were cultured to confluence in standard α-minimum essential medium 
(MEM) supplemented with 10% fetal bovine serum (FBS), 15 L-glutamine and 2% 
penicillin/streptomycin. Prior to seeding the cells were detached from the flasks using trypsin-
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EDTA (Sigma-Aldrich, Dublin, Ireland) and suspended in media to obtain a final concentration 
of 10 x 10
6 
cells per mL. In a 24-well plate, each scaffold was seeded dropwise with 25 µL of the 
cell suspension and then placed in the incubator for 15 min, the scaffolds were then turned over 
and another 25 µL of the cell suspension was added dropwise (total number of cells per scaffold 
= 5 x 10
5
 cells) to produce a cell-seeded construct. After 15 min, 2 mL of either endothelial 
media (for HUVECs) or osteogenic media (for MC3T3-E1 cells; α-MEM supplemented with 
50 µM ascorbic acid 2-P, 100 nM dexamethasone, 10 mM β-glycerophosphate, 10% FBS, 
100 U/mL penicillin, 100 µg/mL streptomycin) was added to each well and the scaffolds returned 
to the incubator. The constructs were cultured for 24 h, 3 and 7 days in the case of HUVECs and 
for 3, 7, 14 and 28 days in the case of MC3T3-E1 cells to allow for mature osteogenesis to take 
place. At each timepoint, constructs were rinsed twice in PBS, flash frozen using liquid nitrogen 
and stored at –80oC until analysis of RNA and DNA content. One scaffold was fixed in 10% 
formalin for histological analysis. Additionally, 1 mL of supernatant was collected and stored at –
80 
o
C until analysis by enzyme-linked immunosorbent assay (ELISA). 
 
2.4.2 Analysis of angiogenesis in bioactive glass/CG scaffolds  
DNA quantification  
Those scaffolds that were flash frozen were digested in lysis buffer containing 1% β-
mercaptoethanol in RLT buffer (Qiagen RNeasy kit, Qiagen, Ireland) and homogenised using a 
rotor-stator homogeniser (Omni International, Germany) and subsequently analysed for DNA 
content as a marker for cell proliferation. Cell lysates were centrifuged using QIA shredder 
columns (Qiagen, Ireland) to remove any scaffold material. The subsequent sample was then 
analysed using the PicoGreen assay according to the manufacturer’s protocol (Quanti-iT 
PicoGreen dsDNA Molecular Probes, OR, USA). 
 
VEGF gene expression 
RNA extraction was carried out using the RNeasy Mini Kit (Qiagen, Ireland) according to 
the manufacturer’s protocol. Expression levels of the angiogenic marker VEGF were investigated 
using quantitative real-time polymerase chain reaction (RT-PCR). Reverse transcriptions (20 μl) 
were performed on 100 ng of total RNA using the QuantiTect Reverse Transcription Kit 
according to the manufacturer’s instructions.  Real-time PCR reactions (15 μl) were performed in 
triplicate on a 7500 Real-Time PCR system (Applied Biosystems, Foster City, CA, USA) using 
the QuantiTect SYBR Green PCR kit (Qiagen, Ireland).  The two predesigned human primers 
  8 
(Qiagen, QuantiTect Primer Assays) that were used were VEGF primer (Hs_VEGFA_6_SG) and 
the housekeeping gene 18s primer (Hs_RRN18S_1_SG).  Relative expression of VEGF was 
determined using the ΔΔCT method [32]. 
 
VEGF protein production 
Media samples were analysed using a VEGF ELISA (Quantikine ELISA kit, R&D 
Systems, Europe) according to the manufacturer’s instructions.  
 
Matrigel assay 
A tubule-forming assay was performed to assess the ability of cobalt released from the 
cobalt bioactive glass/CG scaffold to promote angiogenesis. Briefly, Matrigel™, a basement 
membrane matrix commonly used to observe in vitro angiogenesis, was placed in a 12-well plate 
at 300 µL/well. HUVECs were then plated at a density of 9 x 10
4
 cells per well. Plates were 
placed in an incubator for 20 min after which time 1 mL of endothelial media (without VEGF 
supplement) was added. Transwell inserts containing bioactive glass-free CG and cobalt 
bioactive glass/CG scaffolds were applied on top of the wells. A further 1 mL of media was then 
added to the wells containing the scaffolds. Matrigel cultures were imaged at 6, 12 and 24 h with 
a Leica DMIL microscope (10x objective, DFC420C digital camera). For each group, 5 images 
were taken and analysed using ImageJ. The length of the tubules was used as a quantitative 
measure of angiogenesis.   
 
2.4.3 Analysis of osteogenesis in bioactive glass/CG scaffolds 
DNA and alkaline phosphatase quantification 
DNA content was assessed as described previously. Alkaline phosphatase (ALP) activity 
was assessed at day 7 to demonstrate the ability of the scaffolds to support osteogenesis. At the 
endpoint of the study constructs containing MC3T3-E1 cells were washed in PBS and lysed 
according to the manufacturer’s protocol (SensoLyte pNPP Alkaline Phosphatase Assay Kit). 
Briefly, scaffolds were homogenised in the appropriate lysis buffer and incubated at 4 ºC. This 
method utilized p-nitrophenyl phosphate (pNPP) that is hydrolysed by ALP to produce a yellow 
product. The amount of coloured product is proportional to the amount of enzyme in the reaction. 
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Cell-mediated mineralisation 
To assess cell-mediated matrix mineralisation on the scaffolds in response to cobalt-free 
bioactive glass and cobalt bioactive glass, three different methods were used; alizarin red and von 
Kossa staining, as well as calcium quantification (at day 28). To examine the ability of the 
constructs to produce calcium phosphates, wax-embedded scaffold sections (10 µm) were de-
paraffinized to distilled water and stained with (1) 2% alizarin red (Sigma-Aldrich, Ireland) for 2 
min and then mounted with a coverslip or with (2) 2% silver nitrate solution and exposed to 
ultraviolet light for 20 min prior to mounting. Digital images were obtained as previously 
described. The ability of the bioactive glass-containing CG scaffolds — both cobalt-free and 
cobalt bioactive glasses — to induce mineralisation by pre-osteoblasts was further assessed using 
a calcium quantification technique used routinely in our laboratory [4, 5, 7, 8, 28, 29]. Constructs 
were added to 1 mL of 0.5 M hydrochloric acid, homogenised using a rotor-stator homogeniser 
and incubated overnight at 4 ºC whilst shaking to disassociate calcium from proteins. The 
samples were analysed according to the StanBio Calcium Liquicolour Kit 0150 assay protocol. A 
standard curve was constructed from 0 to 1 µg/mL, and from the equation of the trendline the 
concentration of calcium per sample was obtained.  
 
2.5 Statistical analysis 
Data are represented as mean ± standard deviations. Statistics were carried out using a 
GraphPad Prism software using a general linear model ANOVA with Tukey’s post hoc tests 
performed for multiple comparisons. All cell cultures were performed with a sample size of 3 per 
treatment group. Statistical significance was taken at p<0.05 unless otherwise stated. 
 
3 Results 
3.1 Scaffold fabrication 
A series of preliminary experiments were conducted to establish the optimal scaffold 
fabrication process for the successful introduction of bioactive glass into CG scaffolds. It was 
observed that for all scaffold types the faster cooling rate (4
o
C/min) produced a thin film on the 
scaffold surface that could potentially be problematic for cell attachment and infiltration; 
furthermore a heterogeneous pore structure was observed compared with that seen in scaffolds 
made with the slower cooling rate of 1
o
C/min (Fig. 1). Moreover, the initial analysis 
(supplementary information) showed that the length of time the bioactive glass was in contact 
with the acidic collagen slurry affected the resulting freeze-dried scaffold structure; the addition 
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of the bioactive glass caused the pH of the slurry to increase, causing it to separate. Thus, the 
optimal scaffold fabrication process to reduce this effect and maintain the microstructural 
integrity was determined to be the addition of bioactive glass into the pre-formed CG slurry 
(which was degassed prior to the addition to remove air bubbles) followed by freeze-drying at a 
cooling rate of 1
o
C/min for 24 h at a final freezing temperature of –40°C. These studies resulted 
in a fabrication process that could consistently produce homogenous bioactive glass-containing 
CG scaffolds. 
 
3.2. Physical characterisation of bioactive glass/CG scaffolds 
3.2.1 Release of cobalt from scaffolds 
Only the composites containing 2.8 and 7 mg of cobalt bioactive glass per scaffold 
released cobalt ions in the biologically relevant range of 3–12 ppm sufficient for activation of the 
HIF-1 pathway [25, 33]. However, only those that incorporated 7 mg of bioactive glass per 
scaffold released >3 ppm of cobalt at each of the timepoints examined (day 3 and 7; Fig. 2). The 
ability of the two different sized cobalt bioactive glasses to release cobalt ions at different rates 
based on their varying surface-area-to-volume ratios was investigated. It was observed that the 
particle size of the bioactive glass did not significantly affect the release behaviour of cobalt ions 
(Fig. 2) although smaller particles (38 µm) displayed a trend towards increased ion release at both 
timepoints. 
 
3.2.2 Effect of bioactive glass incorporation on scaffold mechanical properties 
A series of tests were conducted to examine the effects of bioactive glass on the physical 
characteristics of the scaffolds. The compressive moduli of the scaffolds were significantly 
increased by the addition of bioactive glass when compared with the negative control (bioactive 
glass-free CG scaffold; Fig. 3A) showing that the particles reinforce the scaffolds. It was also 
observed that the moduli increased with increasing bioactive glass concentration (data not 
shown). All further in vitro studies were carried out with the composite containing 7 mg of 
bioactive glass per scaffold, which was deemed to be most optimal based on the cobalt release 
kinetics and improved mechanical properties. 
 
3.2.3 Effects of bioactive glass incorporation on scaffold porosity 
Scaffold porosity reduced as a result of the incorporation of bioactive glass compared 
with the control, but was maintained at levels beneficial for cellular and vascular infiltration, and 
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tissue growth. All scaffolds maintained high degrees of porosity of 98% and above (Fig. 3B).  
The scanning electron micrographs in Figure 3C show the highly porous architecture of the 
scaffolds, and an even distribution of bioactive glass was observed throughout the collagen 
matrix.  
 
3.3 Effect of bioactive glass incorporation on biological response  
3.3.1 Analysis of angiogenesis in bioactive glass/CG scaffolds  
To investigate cellular interactions, HUVECs were seeded onto the optimised scaffolds 
(containing 7 mg of bioactive glass per scaffold). Initially, a reduction in cell number was 
observed on scaffolds containing cobalt-free bioactive glass at day 1 and day 3 compared with all 
other groups. However, by day 7, cell numbers were relatively homogenous for the different 
composites examined. There was no significant drop in cell number for scaffolds with the cobalt 
bioactive glass (Fig. 4A) across the time period examined. VEGF gene expression was 
upregulated for scaffolds with cobalt bioactive glass (Fig. 4B). Initially, the smaller-diameter 
cobalt bioactive glass particles showed higher levels after 24 h and 3 days, but by day 7 the 
highest gene expression was observed for scaffolds with the larger-diameter particles. 
Furthermore, VEGF gene expression correlated with VEGF protein production (Fig. 4C) where, 
by day 7, the highest levels of protein were seen for scaffolds with the larger-diameter particles. 
The ability of the cobalt bioactive glass/CG scaffolds to promote tubule formation with HUVECs 
was then assessed using a tubule-formation assay (Fig. 4D). It was observed that HUVECs 
cultured with the dissolution media from cobalt bioactive glass/CG scaffolds displayed enhanced 
vascular tubule formation compared with the bioactive glass-free CG control (Fig. 4D, E) at 4 
and 12 h, further indicating a cobalt bioactive glass-induced angiogenic response. Tubule 
formation was more enhanced in the presence of larger-diameter cobalt bioactive glass particles 
of 100 µm compared with the smaller particles with a mean diameter of 38 µm (Fig. 4E), which 
corroborated the gene and protein data.   
 
3.3.2 Analysis of osteogenesis in bioactive glass/CG scaffolds  
When pre-osteoblastic cell number was assessed as a marker for cell proliferation, there 
was no significant reduction in the presence of bioactive glass (Fig. 5A) compared with the 
bioactive glass-free CG scaffold from day 3 to day 7. At day 14 the CG scaffold alone had the 
highest cell numbers but by day 28 there was no difference in cell numbers on the different 
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scaffolds. Cell numbers increased to a similar extent as the control from day 3 through to day 28 
indicating cellular activity on the scaffolds in the presence of bioactive glass. The osteogenic 
activity of these cells was then measured by monitoring ALP production at day 7. Significant 
effects of the incorporation of cobalt bioactive glass were observed at day 7 (p<0.05). 
Importantly, ALP activity was upregulated (2.6 and 2.2 fold) in the presence of cobalt-eluting 
bioactive glass particles (100 µm and 38 µm, respectively) compared with the CG scaffold. 
Interestingly, cobalt-eluting bioactive glass also promoted enhanced ALP activity compared with 
the cobalt-free bioactive glass/CG scaffold, suggesting a cobalt bioactive glass-induced 
osteogenic response (Fig. 5B). Similarly alizarin red staining of scaffolds that had been cultured 
for 28 days revealed enhanced calcium deposition within the bioactive glass/CG scaffolds 
compared with the CG scaffold alone (Fig. 5C). Cell-mediated calcium production from cells 
seeded on the scaffolds for a period of 28 days was next quantified (Fig. 5D). The results 
corroborated the histological results. Increased calcium deposition was reported in scaffolds 
containing cobalt-free bioactive glass (p<0.001; 38 µm) and, to a lesser extent cobalt-eluting 
bioactive glass. A significant increase was observed in the scaffolds containing smaller cobalt 
bioactive glass particles (38 µm) compared with the CG control.  Taken together, cobalt bioactive 
glass/GC composite scaffolds were shown to enhance angiogenic activity and influence 
osteogenesis.             
    
4. Discussion 
One of the main limitations in regenerative medicine is achieving functionally 
vascularised constructs that can integrate fully with the host tissue on implantation [16]. 
Conventional approaches involving the delivery of therapeutic growth factors aimed at initiating 
angiogenesis and osteogenesis [34] have many limitations leading to potential safety concerns 
within a clinical setting [17]. The focus of this study was to combine resorbable bioactive glasses 
with hypoxia-mimicking cobalt ions with a CG scaffold optimised for bone tissue regeneration. 
The results confirmed the potential of CG scaffolds incorporating cobalt bioactive glass as a 
biomaterials-based approach for bone repair. Inclusion of the cobalt bioactive glass not only 
improved the compressive modulus of the composite scaffolds and maintained high degrees of 
porosity, but it also induced an angiogenic influenced the osteogenic response from endothelial 
and pre-osteoblastic cells, respectively. These composite scaffolds may have significant potential 
in bone tissue regeneration applications negating the need for growth factors, which are often 
expensive, have disputed efficacy and are often associated with non-specific target effects.  
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The development of a fabrication process that could consistently produce homogenous 
cobalt bioactive glass/CG scaffolds was a significant challenge. Bioactive glass stimulates bone 
bonding by forming a hydroxyl carbonate apatite (HCA) layer on the glass surface following 
contact with biological fluid thereby stimulating osteogenesis. The HCA layer is formed as a 
result of a sequence of chemical events that are initiated in the presence of biological fluids. The 
first step is the rapid exchange of Na
+
 and Ca
2+
 with H
+
 or H3O
+
 from the solution, causing 
hydrolysis of the silica groups in the bioactive glass to create silanols. However, the pH of the 
solution increases as a result of the H
+
 ions in the solution being replaced by cations [35]. In this 
study, this initial increase in pH due to cation exchange caused some difficulties for the 
incorporation of the bioactive glass into the CG slurry. Thus, the challenges were to (1) 
incorporate the bioactive glass and (2) to minimise the length of time it spent in the slurry to 
prevent the pH increasing and the slurry subsequently separating. Immediate freezing at a 
controlled cooling rate of 1
o
C/min was found to be optimal as this regime produced a 
homogenous distribution of bioactive glass and pore structure. Previous work has combined 
bioactive glass with collagen sponges via a soak loading method [36], however, directly 
incorporating bioactive glass into a preformed collagen slurry followed by lyophilisation to yield 
a microparticle-loaded scaffold has thus far never been successfully achieved to the best of our 
knowledge. Yet, despite the aforementioned limitations we successfully developed a method to 
fabricate collagen-based scaffolds incorporating cobalt bioactive glass using a lyophilisation 
technique. 
The addition of bioactive glass led to improved mechanical properties. Higher 
compressive moduli were observed with increasing amounts of bioactive glass as a result of the 
reinforcing effect of the particles within the scaffold framework. This effect has previously been 
demonstrated in our laboratory where it has been shown that the incorporation of ceramic 
particles into collagen-based scaffolds led to improved mechanical properties [37, 38].  
Encouragingly, the addition of the bioactive glass did not affect porosity of the CG scaffold; all 
composite scaffolds had porosities above 98%, a level that has been shown to be suitable for 
cellular and vascular infiltration of scaffolds [8].  
The majority of research pertaining to the ability of bioactive glass to induce an 
angiogenic or osteogenic response has been carried out on the soluble dissolution products of 
bioactive glass as reviewed by Hoppe et al. [11]. However, we sought to investigate the effects of 
cells cultured in direct contact with these materials. Previous work has shown that incorporating 
cobalt into mesoporous bioactive glasses represents a viable option for promoting enhanced 
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angiogenesis using human bone marrow stromal cells [39]. Because high concentrations of cobalt 
ions may cause cell toxicity the controlled release of cobalt ions from bioactive glass is therefore 
desirable at concentrations pertinent to HIF-1α stabilisation. Scaffolds containing 7 mg bioactive 
glass per scaffold released cobalt ions within the biologically active concentration range of 3–12 
ppm. This range was previously determined to promote angiogenesis in vitro using endothelial 
cells [22, 33, 40] and in vivo [21], well below cytotoxic levels [39, 41].  
Thus, these scaffolds (containing 7 mg BG per scaffold) were further analysed in vitro to 
assess their ability to promote VEGF gene and protein production as well as tubule formation. 
The mechanism of angiogenesis is coordinated by genes encoding for cytokines and growth 
factors such as VEGF. VEGF has been implicated as a critical regulator of neovascularisation 
[42] and is also fundamental to the osteogenic response in bone healing where it is essential for 
intramembranous and endochondral bone formation [43]. VEGF gene expression at days 1 and 3 
was initially higher in scaffolds containing smaller (38 µm) bioactive glass particles compared 
with the bioactive glass-free CG control and the scaffold with larger particles (100 µm). 
However, by day 7 VEGF gene expression was significantly upregulated in HUVECs cultured on 
scaffolds containing the larger particles (100 µm). Hypoxia, via the HIF pathway mediates a 
broad range of Hypoxia Responsive Element genes  important in regeneration, including a 
number of angiogenic such as VEGF [44]. Cobalt bioactive glasses have previously been shown 
to mimic hypoxia by artificially stabilising HIF-1α leading to enhanced VEGF expression, 
however, a different cellular model that used mesenchymal stem cells was used [26].  
Encouragingly, VEGF gene expression results were further corroborated by the 
observation of enhanced VEGF protein secretion from cells cultured on bioactive glass-
containing scaffolds. Those containing 100-µm-sized particles were found to significantly 
upregulate VEGF protein production (0.5-fold increase) compared with the smaller particles after 
7 days of culture. Further, enhanced tubule formation with a more pronounced tubule length was 
demonstrated in scaffolds containing larger particles compared with those containing smaller 
particles and the bioactive glass-free scaffold at 4 h. The different patterns of VEGF gene and 
protein production between the differently sized bioactive glass particles may be attributed to the 
expected different cobalt release profiles, with smaller particles (38 µm) having a larger surface 
area and therefore eluting cobalt (and other ions) at a faster rate than larger particles (100 µm), 
however, no significant differences in cobalt ion release was observed. Lower concentrations of 
cobalt released from the larger particles at later timepoints may be more beneficial than high 
cobalt concentrations eluted from smaller particles. VEGF protein levels were shown to decrease 
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with time in the bioactive glass-free CG scaffolds whereas enhanced protein secretion was 
recorded from day 3 to 7 in the bioactive glass-loaded scaffolds. The half-life of endogenous 
VEGF mRNA increases during hypoxia [45] and this may explain why VEGF protein 
accumulates with time in cells exposed to cobalt-containing composite scaffolds. Therefore, these 
results indicate that the composite scaffolds initiate a cobalt-induced pro-angiogenic response. 
Some studies suggest that particular compositions of bioactive glass itself indirectly enhances 
angiogenesis, as reviewed elsewhere [46], an effect that was not observed in this study for either 
gene or protein production (data not shown). However, this effect occurs over a very limited 
range of compositions of bioactive glasses with as of yet uncharacterized outcomes [47].  
CG scaffolds [4, 6] have previously been developed to serve as analogues of native 
extracellular matrix [8, 48] for bone repair. However, we hypothesised that in addition to 
enhancing the angiogenic potential of the scaffolds, the osteogenic abilities of the CG scaffold 
may also be improved by the bioactive glass as it well known to have excellent osteoconductive 
and osteoinductive properties [49, 50]. Bioactive glass has shown considerable potential in 
actively promoting osteoblast differentiation via the induction of phenotypic markers such as 
ALP [51-53]. Microarray analysis has also confirmed that solutions containing phosphate, silicon 
and calcium, the primary ionic dissolution products of bioactive glass, are capable of directly 
inducing genes relevant to osteoblast metabolism and the maintenance of extracellular matrix 
[53]. With this in mind the osteogenic potential of the bioactive glass/CG scaffolds was 
investigated by examining the ability to induce growth and differentiation of MC3T3 pre-
osteoblast-like cells. Cell number was shown to be significantly reduced in the presence of 
bioactive glass. Ion-induced cell death such as from calcium ions [54] may account for the 
reduced cell numbers due to the initial ion release from the bioactive glass causing a change in 
the pH of the surrounding media, an effect that could be minimized in the in vivo environment. 
ALP, an early marker for osteogenic differentiation, was significantly increased in cells cultured 
on scaffolds containing cobalt-eluting bioactive glass particles (irrespective of particle size) 
compared with the bioactive glass-free CG scaffold and the cobalt-free bioactive glass-containing 
scaffold. The calcium quantification results further show that scaffolds containing bioactive glass 
were capable of promoting differentiation of pre-osteoblasts to a mature mineral depositing 
osteoblast.  Calcium deposition was the highest in the presence of cobalt-free bioactive glass and 
less pronounced with cobalt bioactive glass. Thus, CG scaffolds, containing cobalt bioactive 
glass particles, may potentially provide a better environment for bone tissue formation or 
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biosynthesis compared with the traditional CG scaffold both in terms of enhancing cell-mediated 
osteogenesis as well as being mechanically superior. 
The delivery of tissue-inductive factors in the form of cobalt bioactive glass, from an 
osteoconductive substrate such as CG scaffolds, offers considerable potential for enhanced bone 
tissue repair and regeneration. The importance of the interplay between angiogenesis and bone 
formation has previously been reported with several studies suggesting the synergism between 
the two processes leads to increased bone healing [55]. The presentation of multiple regulatory 
signals is essential for many tissue regeneration processes and may thus be a prerequisite for the 
design of more advanced tissue-engineered materials.. Taken together, the results indicate for the 
first time that hypoxia bioactive glass composite scaffold are capable of promoting angiogenesis 
and supporting osteogenesis..  
 
5. Conclusions 
 We have combined novel hypoxia-mimicking cobalt bioactive glasses with CG scaffolds 
optimised for bone repair. The results have demonstrated that these scaffolds may create a 
microenvironment capable of stimulating both angiogenesis and vascularisation via the release of 
cobalt, a known hypoxia mimic, as well as supporting osteogenesis as a result of the 
osteoinductive bioactive glass particles. Overall, this study indicates that an angiogenic response 
may be achievable through a growth factor-free biomaterials-based approach. 
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Figures 
 
Fig. 1 Pore structure of scaffolds. Toluidine Blue-stained images of cobalt bioactive glass/collagen–glycosaminoglycan 
scaffolds made at controlled freezing rates of (A) 1
o
C/min and (B) 4
o
C/min. A more homogenous pore structure for the 
composite scaffolds frozen at 1
o
C/min was demonstrated. Particles with a mean diameter of 100 m were used. Scale bars, 
500 m. 
 
 
Fig. 2 Release of cobalt ions from the bioactive glass/collagen–glycosaminoglycan composites measured using 
Inductively Coupled Plasma-Mass Spectrometry (ICP-MS). The results show the release of cobalt after 24 h and the 
cumulative release at 7 days. Scaffolds incorporating 7 mg of bioactive glass per scaffold, released cobalt in the 
biologically active range of 3–12 ppm, which is the limit for HIF-1a activation (dashed lines).  
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Fig. 3 Physical characterisation of bioactive glass/collagen–glycosaminoglycan (CG) scaffolds. (A) The addition of 
bioactive glass increases the compressive modulus of the scaffolds. Note that there is no significant difference in the 
stiffness with respect to the different types of bioactive glass. A concentration of 7 mg bioactive glass per scaffold 
was used. (B) Porosity of composites (7 mg bioactive glass per scaffold) was reduced compared with the bioactive 
glass-free CG scaffold, but was maintained at levels beneficial for cell and vascular infiltration. (C) Scanning 
electron micrographs of the bioactive glass-free CG scaffold and bioactive glass/CG scaffolds showing the 
incorporation of bioactive glass (white arrows) within the collagen matrix as well as the pore structure.  Scale bars, 
50 µm. *** P<0.001. 
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Fig. 4 Angiogenesis in bioactive glass/collagen–glycosaminoglycan (CG) scaffolds. (A) Number of endothelial cells 
on scaffolds at 1, 3 and 7 days post-seeding. An initial seeding density of 500,000 cells per scaffold was used. Cell 
numbers were initially higher in the bioactive glass-free CG scaffolds but were maintained at similar levels in all 
groups by 7 days. (B) Vascular Endothelial Growth Factor (VEGF) gene expression in HUVECs cultured on 
bioactive glass-free CG and bioactive glass-containing CG scaffolds at 1, 3 and 7 days. All data is normalized to the 
24 h negative control (bioactive glass-free CG). (C) VEGF protein concentration in bioactive glass-containing CG 
composites seeded with HUVECs up to 7 days. There is a significant increase in concentration versus bioactive 
glass-free CG control at day 7. (D) Bright-field images of tubule formation. More mature networks are observed in 
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bioactive glass-containing CG scaffolds at 4 h. Scale bars, 100 µm. (E) Tubule length quantification showing that 
cobalt bioactive glass/CG scaffolds lead to enhanced tubule formation. * P<0.05; ** P<0.01.  
 
 
 
Fig. 5 Osteogenesis in bioactive glass/collagen–glycosaminoglycan (CG) scaffolds. (A) Increase in pre-osteoblast 
cell number on different scaffolds at days 3, 7, 14 and 28 compared with the CG scaffold with 38- and 100-µm-
diameter cobalt bioactive glass particles. (B) Alkaline phosphatase activity increased in the presence of cobalt-
eluting CG scaffolds compared with the bioactive glass-free CG scaffold and cobalt-free bioactive glass-containing 
scaffold. (C) Bright-field images of alizarin red-stained scaffolds demonstrating enhanced deposition in the bioactive 
glass-containing scaffolds relative to the bioactive glass-free control at 28 days (i). Staining was most intense for the 
cobalt-free bioactive glass-containing CG groups (ii), followed by the cobalt-eluting CG scaffolds (iii, iv) containing 
small and large-diameter bioactive glass particles. Scale bars, 500 µm. (D) There was an increase in calcium levels in 
the bioactive glass-containing CG scaffolds, the highest levels were seen in the group containing the larger-diameter 
bioactive glass particles. * P<0.05; ** P<0.01; ***P<0.001. 
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Supplementary figure 
 
Supplementary S1: Pore structure of scaffolds. Toluidine Blue-stained images of cobalt bioactive glass/collagen–
glycosaminoglycan scaffolds made by degassing the CG slurry prior to the addition of bioactive glass (A) and following the 
addition of BG (B) made at a controlled freezing rate of 1
o
C/min. Composite scaffolds which were degassed prior to the 
addition of bioactive glass maintained their microstructural integrity and displayed a homogenous pore structure. Particles 
with a mean diameter of 100 µm were used. Scale bars, 500 µm. 
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